JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on May 14.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy’s rating is based on the promising developments and future potential of Janux Therapeutics Inc. The company is expected to release additional data from its Phase 1 trials for JANX007 and JANX008 in the second half of 2025, which could significantly impact its market position. JANX007, a T cell engaging antibody, is anticipated to compete with Pluvicto, a product that has already captured a substantial market share despite its complex administration. If JANX007 demonstrates comparable efficacy to Pluvicto, it could lead to faster market adoption and make Janux an attractive target for mergers and acquisitions.
Furthermore, the safety profile of JANX007, particularly regarding steroid use post-CRS resolution, will be crucial. A favorable safety outcome, especially with the Q2W dosing regimen showing similar efficacy but improved safety compared to the current weekly schedule, could enhance investor interest. Additionally, the patient population in the ENGAGER trial will be monitored closely, particularly those eligible for chemotherapy and AR therapy changes, which could further influence the stock’s attractiveness.
In another report released on May 14, Bank of America Securities also maintained a Buy rating on the stock with a $64.00 price target.